NSE · Healthcare · Diagnostics & Research
EPS came in at -0.07 against a street estimate of 1.44 — a miss of 104.9%.
with an average price target of ₹501.88.
MIXED New CEO appointed; FY27 transition year with single-digit revenue decline guidance due to loss of major Zoetis contract. Focusing on CDMO, AI-led discovery, and clinical trials. Mid-20% EBITDA margin guided; recovery expected FY28 onwards. Q1 FY27 Clinical trials hindered by slow Indian regulatory approvals for first-in-human and Phase I/II; using international partnerships to accelerate. Bayview in U.S. benefits from Biosecure Act tariff shifts. Analysts pressed on Zoetis revenue gap fill timeline, CDMO pipeline visibility (Bayview/Stelis traction), and margin recovery mechanics. Management emphasized H2 momentum, deliberate exit from low-margin work, and need for one quarter to provide quantified FY28+ guidance. 2026-07-30…
Full summary in the app.
| Document | Date |
|---|---|
| Q1 FY27 earnings call | 2026-08-06 |
| Investor presentation SYNGENE INTERNATIONAL LIMITED – INVESTOR SUMMARY Q1 FY27 (Quarter ended June 30, 2026) --- HEADLINE NUMBERS • Revenue from Operations: Rs 736 Cr, d | 2026-07-29 |
| Annual report FY2026 SYNGENE INTERNATIONAL LIMITED – FY 2025-26 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue from operations: Rs 37,387 Mn (3% year-on-year gr | 2026-07-02 |
| Q4 FY26 earnings call DOCUMENT SUMMARY: SYNGENE INTERNATIONAL LIMITED IMPORTANT NOTE This document is a regulatory filing notice only – it merely intimates that an earning | 2026-05-04 |
| Investor presentation · Q4 FY26 SYNGENE INTERNATIONAL LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Revenue from Operations: Rs 3,739 Cr (~USD 419 Mn), grew 3% year-on-year • | 2026-04-30 |
| Quarterly results · Q4 FY26 SYNGENE INTERNATIONAL LIMITED - INVESTOR SUMMARY HEADLINE NUMBERS • FY 2025-26 Standalone Revenue from Operations: Rs. 34,238 million (vs Rs. 33,733 | 2026-04-29 |
| Q3 FY26 earnings call SYNGENE INTERNATIONAL LIMITED – Q3 & 9M FY2026 SUMMARY HEADLINE NUMBERS • Q3 FY2026 Revenue: Rs.917 crores, down 3% year-on-year (down 7% in constan | 2026-01-29 |
| Investor presentation · Q3 FY26 SYNGENE INTERNATIONAL LIMITED – INVESTOR SUMMARY January 2026 Investor Presentation --- HEADLINE NUMBERS • Q3 FY26 Revenue from Operations: Rs 917 | 2026-01-23 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹1.25 / share ex-date Jun 25, 2026 · record Jun 26, 2026 | 2026-06-25 |
| Announcement | Date |
|---|---|
| Acquisition announced by Syngene International Limited Syngene International Limited, a pharmaceutical/biotech company, has announced an investment of Rs. 2.52 crores (Rs. 25.2 million) in Ampin C&I Power Twelve Private Limited, a newly formed r | 2026-08-24 |
| Acquisition announced Syngene International Limited has informed the Exchange about Acquisition | 2025-12-23 |
| Expands biologics facility with new ADC bioconjugation capability Syngene International Limited, a contract research and manufacturing organization, announced an expansion of its biologics facility to include new ADC (Antibody-Drug Conjugate) bioconjugatio | 2025-10-24 |
| Expands biologics facility with new ADC bioconjugation capability The Indian stock exchange (likely BSE or NSE) has requested clarification from Syngene International Limited regarding a recent news announcement about the company expanding its biologics fa | 2025-10-23 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Syngene International Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.